Galderma Acquires Spirig of Switzerland

Spirig’s products treat conditions such as solar damage and skin barrier function impairment.In addition, the company has a range of medically-proven products that prevent pre-cancerous conditions, such as actinic keratosis, a type of non-melanoma skin cancer. Leading brands include Excipial, Daylong and Daylong Actinica.

“We are delighted to join forces with Spirig Pharma” said Humberto C. Antunes, CEO of Galderma: “Spirig has a holistic approach to protecting, treating, restoring and preventing dermatological conditions which is closely aligned to that of Galderma. With this acquisition, Galderma will become the dermatology market leader in Switzerland, our home country. Additionally, with our global presence, we will be able to make Spirig’s outstanding products available to a larger number of patients around the world.”

“Galderma fulfils all the stringent criteria we set when we started looking for a new owner,” said Dr. Beat Sägesser, CEO of Spirig. “Becoming part of Galderma will provide Spirig with the ideal conditions in which to develop and take its business to a new level and provide new opportunities for our employees”.

“We are excited about our two companies’ commercial and geographic opportunities, maximizing the value of our complementary product portfolios in the prescription and self-medication markets,” said Albert Draaijer, Galderma’s VP, business development and markets, who also leads Galderma’s Self-Medication and Aesthetic and Corrective businesses.”We look forward to welcoming Spirig employees and to combining our efforts to better meet the market’s needs.”

With activities focused on dermatological prescription, over-the-counter drugs and aesthetic and corrective medical solutions and with an extensive product portfolio available in 70 countries, Galderma sales were approximately $1.7 billion in 2011.